628. Aggressive Lymphomas: Cellular Therapies: Poster III

Subgroup analysis in pediatric patients from the Phase 3 study of tabelecleucel for allogeneic or solid organ transplant recipients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease

Outcomes of autologous transplant ASCT in patients with chemosensitive late relapse of large B cell lymphoma LBCL

Trial in progress A phase 2 randomized trial of remodeling intestinal microbiota using fecal microbiome transplant FMT among recipients of chimeric antigen receptor T cells CAR T

Lymphocyte kinetics as a predictor of clinical outcomes following CAR T therapy for non Hodgkin lymphoma

Late immune effector cell associated hematotoxicity ICAHT in patients with relapsed refractory large B cell lymphoma receiving anti CD19 chimeric antigen receptor T cell therapy

Comparative CRS risk across CAR T constructs in DLBCL in real world cohorts

Prognostic impact of CAR T cell expansion and PD1 expression in patients with DLBCL treated with axicabtagene ciloleucel

Large B cell lymphoma following CD19 directed CART cell therapy failure Impact of CAR construct on disease features and outcomes of subsequent therapies

Pattern of infections and impact on immunocompetence of next generation B cell depleting immunotherapies in non Hodgkin s lymphomas Results from a multicentre retrospective real life cohort

The cns IPI score is predictive of severe immune effector cell associated neurotoxicity after axicabtagene ciloleucel treatment in patients with large B cell lymphoma

Central nervous system relapse is uncommon after chimeric antigen receptor T cell therapy for relapsed refractory large B cell lymphoma

Poor neutrophil recovery following CD19 targeted CAR T cell therapy predicts inferior outcomes in adult patients with B cell lymphoma

Patterns risk factors and management of CD19 directed chimeric antigen receptor T cell therapy failure in CNS lymphoma

Low serum IgG at apheresis predicts delayed humoral immune reconstitution and increased risk of infections after CD19 CAR T cell therapy for B cell lymphoma

Multiple time point FDG PET imaging for risk stratification of patients with relapsed refractory large B cell lymphoma undergoing CD19 directed CAR T cell therapy

Genomic heterogeneity and prognostic implications in CAR t treated relapsed refractory primary CNS lymphoma

Pre treatment eosinophil levels correlate with superior clinical outcomes in high tumor burden DLBCL patients receiving CD19 CAR T cell therapy

Consolidation with loncastuximab tesirine for large B cell lymphoma patients in partial response after CART Planned interim futility analysis of a phase II trial

Transplantation in combination with CAR T cell therapy for refractory relapsed aggressive B cell lymphoma after failure of CD19 CAR T cell therapy

Outpatient OP use of lisocabtagene maraleucel liso cel in patients Pts with relapsed or refractory R R large B cell lymphoma LBCL Real world data from the CIBMTR registry